CA3142462A1 - Leader sequence - Google Patents

Leader sequence Download PDF

Info

Publication number
CA3142462A1
CA3142462A1 CA3142462A CA3142462A CA3142462A1 CA 3142462 A1 CA3142462 A1 CA 3142462A1 CA 3142462 A CA3142462 A CA 3142462A CA 3142462 A CA3142462 A CA 3142462A CA 3142462 A1 CA3142462 A1 CA 3142462A1
Authority
CA
Canada
Prior art keywords
pvc
effector
seq
payload
leader sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142462A
Other languages
English (en)
French (fr)
Inventor
Nicholas R. Waterfield
Joseph HEALEY
Alexia HAPESHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanosyrinx Ltd
Original Assignee
University of Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Warwick filed Critical University of Warwick
Publication of CA3142462A1 publication Critical patent/CA3142462A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA3142462A 2019-06-07 2020-06-05 Leader sequence Pending CA3142462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1908155.3 2019-06-07
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
CA3142462A1 true CA3142462A1 (en) 2020-12-10

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142462A Pending CA3142462A1 (en) 2019-06-07 2020-06-05 Leader sequence

Country Status (12)

Country Link
US (1) US20230076614A1 (https=)
EP (1) EP3980545A1 (https=)
JP (2) JP7748288B2 (https=)
KR (1) KR20220133757A (https=)
CN (1) CN114008205A (https=)
AU (1) AU2020288380A1 (https=)
BR (1) BR112021024592A2 (https=)
CA (1) CA3142462A1 (https=)
GB (1) GB201908155D0 (https=)
MX (1) MX2021015121A (https=)
SG (1) SG11202113297RA (https=)
WO (1) WO2020245611A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158486A2 (en) * 2022-02-15 2023-08-24 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
WO2024003387A1 (en) 2022-06-30 2024-01-04 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2964240B1 (en) * 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
WO2017066479A1 (en) * 2015-10-14 2017-04-20 Bayer Cropscience Lp Axmi554 delta-endotoxin gene and methods for its use

Also Published As

Publication number Publication date
BR112021024592A2 (pt) 2022-01-18
US20230076614A1 (en) 2023-03-09
JP2025114573A (ja) 2025-08-05
JP2022535283A (ja) 2022-08-05
GB201908155D0 (en) 2019-07-24
AU2020288380A1 (en) 2022-01-06
CN114008205A (zh) 2022-02-01
EP3980545A1 (en) 2022-04-13
MX2021015121A (es) 2022-03-17
KR20220133757A (ko) 2022-10-05
JP7748288B2 (ja) 2025-10-02
WO2020245611A1 (en) 2020-12-10
SG11202113297RA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
Cianfanelli et al. VgrG and PAAR proteins define distinct versions of a functional type VI secretion system
Bagheri et al. Mode of action of cationic antimicrobial peptides defines the tethering position and the efficacy of biocidal surfaces
Ma et al. An IcmF family protein, ImpLM, is an integral inner membrane protein interacting with ImpKL, and its walker a motif is required for type VI secretion system-mediated Hcp secretion in Agrobacterium tumefaciens
JP2025114573A (ja) リーダー配列
Santin et al. Domestication of a housekeeping transglycosylase for assembly of a Type VI secretion system
US10131888B2 (en) Intracellular protein delivery
Vigneux et al. The xaxAB genes encoding a new apoptotic toxin from the insect pathogen Xenorhabdus nematophila are present in plant and human pathogens
Zhao et al. Nisin-and ripcin-derived hybrid lanthipeptides display selective antimicrobial activity against Staphylococcus aureus
Koo et al. Functional mapping of PilF and PilQ in the Pseudomonas aeruginosa type IV pilus system
González-Magaña et al. The P. aeruginosa effector Tse5 forms membrane pores disrupting the membrane potential of intoxicated bacteria
Guo et al. Lipidated variants of the antimicrobial peptide nisin produced via incorporation of methionine analogs for click chemistry show improved bioactivity
KR20030074702A (ko) 모듈식 트랜스펙션 시스템
CN107022001A (zh) 一种分离的母乳内源性抗菌多肽及其应用
US20240254169A1 (en) Protein and peptide delivery systems and methods for making and using them
Kado The role of the T-pilus in horizontal gene transfer and tumorigenesis
CN114908077A (zh) 噬菌体裂解酶、其嵌合物及应用
Velázquez et al. Tke5 is a novel Pseudomonas putida toxin that depolarises membranes killing plant pathogens
Taylor et al. Prophages block cell surface receptors to ensure survival of their viral progeny
Kim et al. A nopA deletion mutant of Sinorhizobium fredii USDA257, a soybean symbiont, is impaired in nodulation
KR20210066752A (ko) 신규한 세포막 투과성 단백질 및 이의 용도
US10329330B2 (en) JC polyomavirus VLP (virus-like particle) with a targeting peptide
Steiner-Rebrova et al. N-terminal toxin signal peptides efficiently load therapeutics into a natural nano-injection system
US20220290114A1 (en) Antimicrobial endolysin polypeptides, compositions and formulations
US20260015391A1 (en) Compositions for hypervesiculating gut microbes and therapeutic enzyme delivery and methods of use thereof
Ramirez Mechanism and Function of Membrane Homeostasis of Sortase Modulated by an Evolutionarily Conserved Protein Involved in Pilus Assembly in Actinobacteria

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240603

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250527

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260317

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260318

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260318